Meclonazepam

Meclonazepam[1] ((S)-3-methylclonazepam) was discovered by a team at Hoffmann-La Roche in the 1970s and is a drug which is a benzodiazepine derivative similar in structure to clonazepam.[2] It has sedative and anxiolytic actions like those of other benzodiazepines,[3] and also has anti-parasitic effects against the parasitic worm Schistosoma mansoni.[4]

Meclonazepam
Clinical data
ATC code
  • none
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC16H12ClN3O3
Molar mass329.74 g/mol g·mol−1
3D model (JSmol)
 NY (what is this?)  (verify)

Meclonazepam was never used as medicine and instead appeared online as a designer drug.[5][6][7]

United Kingdom

In the UK, meclonazepam has been classified as a Class C drug by the May 2017 amendment to The Misuse of Drugs Act 1971 along with several other designer benzodiazepine drugs.[8]

See also

References
  1. U.S. Patent 4,031,078
  2. The Lundbeck Institute. "Meclonazepam". Psychotropics. Lundbeck.
  3. Ansseau, M.; Doumont, A.; Thiry, D.; Von Frenckell, R.; Collard, J. (1985). "Initial study of methylclonazepam in generalized anxiety disorder. Evidence for greater power in the cross-over design". Psychopharmacology. 87 (2): 130–135. doi:10.1007/bf00431795. PMID 3931136.
  4. O'Boyle, C.; Lambe, R.; Darragh, A. (1985). "Central Effects in Man of the Novel Schistosomicidal Benzodiazepine Meclonazepam". European Journal of Clinical Pharmacology. 29 (1): 105–108. doi:10.1007/bf00547377. PMID 4054198.
  5. Markus R. Meyer; Madeleine Pettersson Bergstrand; Anders Helander; Olof Beck (May 2016). "Identification of main human urinary metabolites of the designer nitrobenzodiazepines clonazolam, meclonazepam, and nifoxipam by nano-liquid chromatography-high-resolution mass spectrometry for drug testing purposes". Analytical and Bioanalytical Chemistry. 408 (13): 3571–3591. doi:10.1007/s00216-016-9439-6. PMID 27071765.
  6. Pettersson Bergstrand M, Helander A, Hansson T, Beck O (2016). "Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays". Drug Test Anal. 9 (4): 640–645. doi:10.1002/dta.2003. PMID 27366870.
  7. Manchester, Kieran R.; Maskell, Peter D.; Waters, Laura (2018). "Experimental versus theoretical log D7.4, pKa and plasma protein binding values for benzodiazepines appearing as new psychoactive substances" (PDF). Drug Testing and Analysis. 10 (8): 1258–1269. doi:10.1002/dta.2387. ISSN 1942-7611. PMID 29582576.
  8. "The Misuse of Drugs Act 1971 (Amendment) Order 2017".

Further reading
  • Abdul-Ghani, R. A.; Loutfy, N.; Hassan, A. (2009). "Experimentally promising antischistosomal drugs: A review of some drug candidates not reaching the clinical use". Parasitology Research. 105 (4): 899–906. doi:10.1007/s00436-009-1546-2. PMID 19588166.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.